Newsroom | Medtronic | 2018 Press Releases

2018 Press Releases

Search News Releases
02/16/18Medtronic Chairman and CEO Omar Ishrak to Speak at CEO Investor Forum 3.0
DUBLIN - February 16, 2018 - Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced it will participate in the CECP CEO Investor Forum 3.0 in New York on Monday, February 26, 2018, at 4:00 p.m. EST. Omar Ishrak, chairman and chief executive officer of Medtronic, will make a formal presentation on the company beginning at 4:00 p.m. EST (3:00 p.m. CST).  A live audio webcast of the presentation will be available on February 26, 2018, by clicking on the Investor Even... 
 Printer Friendly Version
02/15/18New Pediatric At-Home Study of MiniMed(TM) 670G System Demonstrates Positive Results in Children Ages 7 to 13
DUBLIN and VIENNA - February 15, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that new data from its at-home pediatric study of the MiniMed(TM) 670G system in patients 7-13 years of age were presented at the Advanced Technologies & Treatments for Diabetes (ATTD) 11th International Conference in Vienna, Austria. Study results mirror data from the pivotal trial of the system in adults and adolescents (14 and above), showing patients spent more Time in R... 
Download PDFPrinter Friendly Version
02/13/18Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2018
DUBLIN - February 13, 2018 - Medtronic plc (NYSE: MDT) announced today that it will report financial results for the third quarter of fiscal year 2018 on Tuesday, February 20, 2018. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at The news release will include summary financial information for the company's third quarter of fiscal year 2018, which ended on Friday, January 26, 2018. Medtronic will host a... 
Download PDFPrinter Friendly Version
02/13/18Medtronic Announces Upcoming Data Presentations at the Advanced Technologies and Treatments for Diabetes 11th International Conference
Medtronic Will Host an Exclusive Symposium on Thursday, February 15 VIENNA - February 13, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its schedule of notable sessions that will be presented at the Advanced Technologies & Treatments for Diabetes (ATTD) 11th International Conference in Vienna, Austria, from February 14-17. A significant portion of the scientific data being presented focuses on the company's insulin pump systems, including new data on ... 
Download PDFPrinter Friendly Version
01/30/18Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region
DUBLIN and SHANGHAI - January 30, 2018 - Medtronic plc (NYSE:MDT) today announced that Alex Gu, previously Vice President, Regional Growth Initiatives, Greater China, and leader of Medtronic's Minimally Invasive Therapies Group (MITG) in Greater China, has been named Senior Vice President and President of Medtronic's Greater China Region. Medtronic's Greater China Region includes mainland China, Hong Kong SAR, and the Taiwan region. Gu will serve on the company's Executive Committee and succeeds... 
Download PDFPrinter Friendly Version
01/30/18Medtronic and Philips Partner to Innovate in Lung Cancer Management
Healthcare Leaders Join to Streamline and Optimize the Management of Lung Nodules DUBLIN and AMSTERDAM - January 30, 2018 - In a collective effort to improve the management of patients with lung nodules, Medtronic plc (NYSE: MDT) and Royal Philips (NYSE: PHG; AEX: PHIA) have entered into a business relationship to develop and commercialize the LungGPS(TM) Patient Management Platform. The comprehensive patient and data management platform is designed to streamline the management of lung nodule ... 
Download PDFPrinter Friendly Version
01/30/18IN.PACT Admiral Demonstrates Consistent and Durable Outcomes in New Two-Year Japan Data and IN.PACT Global Critical Limb Ischemia Cohort Analysis
Data Presented at LINC 2018 Highlight IN.PACT Admiral as Safe and Effective Treatment Option in PAD DUBLIN and LEIPZIG - January 30, 2018 - Medtronic plc (NYSE: MDT) today added to its robust body of clinical evidence supporting the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) with new presentations that demonstrated durable and consistent clinical outcomes in peripheral artery disease (PAD). The new data presented at the Leipzig Interventional Course (LINC) in Leipzig, Germany, included t... 
Download PDFPrinter Friendly Version
01/26/18Medtronic Launches IDE Study to Evaluate the Abre(TM) Venous Self-Expanding Stent System in Patients with Deep Venous Disease
Study to Enroll Subjects at up to 35 Sites Across the U.S. and Europe DUBLIN - January 26, 2018 - Medtronic plc (NYSE: MDT) today announced the initiation of its investigational device exemption (IDE) study for the Abre(TM) venous self-expanding stent system. The ABRE IDE Study will evaluate the safety and effectiveness of the Abre stent in subjects with iliofemoral venous outflow obstruction. The first procedure was performed in December of 2017, by Dr. Erin Murphy, director of the venous and ... 
Download PDFPrinter Friendly Version
01/24/18Medtronic Launches ENCHANT Study to Evaluate ChEVAR Parallel Graft Technique with the Endurant(TM) II/IIs Stent Graft System
Clinical Study to Investigate the Performance of the ChEVAR Technique in AAA Patients with Short Aortic Necks DUBLIN - January 24, 2018 - Medtronic plc (NYSE: MDT) today announced the launch of the ENCHANT (ENdurant CHEVAR New Indication Trial) study. The post-market, non-interventional, multi-center, non-randomized, single-arm study will enroll approximately 150 patients across 25 sites in Europe and Russia, and will evaluate the safety and performance of a ChEVAR procedure using the Endurant... 
Download PDFPrinter Friendly Version
01/16/18Medtronic Receives FDA Clearance for Riptide(TM) Aspiration System
New System Expands Neurovascular Product Portfolio for the Treatment of Acute Ischemic Stroke DUBLIN - January 16, 2018 - Medtronic plc (NYSE:MDT) today announced that the company's Neurovascular business unit received U.S. Food and Drug Administration (FDA) clearance of the Riptide(TM) Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio. The Riptide Aspiration System is designed to retrieve thrombus (or blood clot) through the Arc(TM) Catheter and r... 
Download PDFPrinter Friendly Version
01/11/18New Study Shows Superiority of Intrathecal Baclofen Therapy (ITB Therapy(SM)) Over Oral Medication for the Treatment of Severe Post-Stroke Spasticity
Therapy Delivered via the Medtronic SynchroMed(TM) II Infusion System DUBLIN - January 11, 2018 - Medtronic plc (NYSE:MDT) today announced the publication of results from the 'Spasticity In Stroke-Randomised Study' (SISTERS) trial in the Journal of Neurology, Neurosurgery & Psychiatry (JNNP). These results demonstrate the superiority of Medtronic ITB TherapySM with Lioresal®Intrathecal (baclofen injection) delivered via the SynchroMed(TM) II Infusion System compared to conventional medical ... 
 Printer Friendly Version
01/10/18FDA Approves Innovative Clinician Programmer for the Medtronic SynchroMed II Intrathecal Drug Delivery System for Chronic Pain and Severe Spasticity
SynchroMed(TM) II for Chronic Pain Is an Alternative to Systemic Opioids for Many Patients DUBLIN - January 10, 2018 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of a new clinician programmer for use with the SynchroMed(TM)II Intrathecal Drug Delivery system, an implantable pump that provides targeted drug delivery for chronic pain and severe spasticity. The SynchroMed II pump delivers medication directly to the fluid around the spinal cord, which... 
Download PDFPrinter Friendly Version
01/09/18Medtronic Enrolls First Patient In Pain Study to Assess Optimized Spinal Cord Stimulation Programming
As More Physicians Seek Non-Opioid Treatment Options, the Vectors Study Will Further Advance Understanding of New Approaches to Optimal Spinal Cord Stimulation Treatment DUBLIN - January 9, 2018 - Medtronic plc (NYSE:MDT) today announced the first patient enrolled in the Vectors Post Market Clinical Study. The study will follow patients with chronic intractable pain who are undergoing spinal cord stimulation (SCS) treatment managed with the EvolveSM workflow*, which standardizes guidance that ... 
Download PDFPrinter Friendly Version